Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
February 2018
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasisTwo thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
-
Media ReleaseNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
-
Media ReleaseNovartis forms alliance to develop medicines for treating infectious diarrheal diseaseNovartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
-
Media ReleaseSandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosisGlatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
-
Potential weight loss treatment takes shape with help from patients
Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasisUS label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
-
Compound designed to fight Alzheimer’s disease shows promise in the lab
The molecule restores the activity of neurons and neural circuits in a model of the disease.
-
Partnering for improved cancer care around the globe
Novartis works tirelessly with third-party organizations to improve access to cancer care.
-
Living with breast cancer in Uganda
Suzan Akello describes what life has been like since her cancer diagnosis.
-
Key ReleaseNovartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
January 2018
-
Media ReleaseNovartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALLAnalysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with…
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three PatientsCHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
Pagination
- ‹ Previous page
- 1
- …
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- …
- 151
- › Next page